Page 141 - 《中国药科大学学报》2025年第4期

第 56 卷第 4 期 周 珂，等：疟疾疫苗的研发进展 537

改进免疫原结构和优化蛋白质合成来发现、验证新 length Plasmodium falciparum merozoite surface protein 1 is
的抗原和递送系统，提高候选疫苗的保护效力和持 safe and elicits functional cytophilic antibodies in a randomized
first-in-human trial[J]. NPJ Vaccines, 2020, 5(1): 10.
久性，进一步降低疟疾发病率和病死率，达到保护 [16] Rosenkranz M, Fürle K, Hibbert J, et al. Multifunctional
人类健康的目的。 IgG/IgM antibodies and cellular cytotoxicity are elicited by the
full-length MSP1 SumayaVac-1 malaria vaccine[J]. NPJ Vac-
cines, 2023, 8(1): 112.
References
[17] Douglas AD, Baldeviano GC, Lucas CM, et al. A PfRH5-based
[1] World Health Organization. World malaria report 2023 [R]. vaccine is efficacious against heterologous strain blood-stage
Geneva: World Health Organization, 2023. https://www. Plasmodium falciparum infection in Aotus monkeys[J]. Cell
who.int/publications/i/item/9789240086173. Host Microbe, 2015, 17(1): 130-139.
[2] World Health Organization. Global technical strategy for malar- [18] Silk SE, Kalinga WF, Mtaka IM, et al. Superior antibody im-
ia 2016-2030 [R]. Geneva: World Health Organization, 2015, munogenicity of a viral-vectored RH5 blood-stage malaria vac-
[2023]. https://iris.who.int/handle/10665/176712. cine in Tanzanian infants as compared to adults[J]. Med, 2023,
[3] Zhang L, Xia ZG. Epidemiological characteristics of malaria in 4(10): 668- 686. e7.
China, 2023[J]. Chin J Parasitol Parasit Dis (中国寄生虫学与 [19] Minassian AM, Silk SE, Barrett JR, et al. Reduced blood-stage
寄生虫病杂志), 2024, 42(2): 135-139. malaria growth and immune correlates in humans following
[4] Mihreteab S, Platon L, Berhane A, et al. Increasing prevalence RH5 vaccination[J]. Med, 2021, 2(6): 701- 719. e19.
of artemisinin-resistant HRP2-negative malaria in Eritrea[J]. N [20] Sirima SB, Richert L, Chêne A, et al. PRIMVAC vaccine adju-
Engl J Med, 2023, 389(13): 1191-1202. vanted with Alhydrogel or GLA-SE to prevent placental malar-
[5] Mariano RMDS, Gonçalves AAM, Oliveira DS, et al. A review ia: a first-in-human, randomised, double-blind, placebo-con-
of major patents on potential malaria vaccine targets[J]. trolled study[J]. Lancet Infect Dis, 2020, 20(5): 585-597.
Pathogens, 2023, 12(2): 247. [21] Gamain B, Chêne A, Viebig NK, et al. Progress and insights to-
[6] RTS, S Clinical Trials Partnership. Efficacy and safety of RTS, ward an effective placental malaria vaccine[J]. Front Immunol,
S/AS01 malaria vaccine with or without a booster dose in in- 2021, 12: 634508.
fants and children in Africa: final results of a phase 3, individu- [22] Mordmüller B, Sulyok M, Egger-Adam D, et al. First-in-hu-
ally randomised, controlled trial[J]. Lancet, 2015, 386(9988): man, randomized, double-blind clinical trial of differentially ad-
31-45. juvanted PAMVAC, a vaccine candidate to prevent pregnancy-
[7] Dicko A, Ouedraogo JB, Zongo I, et al. Seasonal vaccination associated malaria[J]. Clin Infect Dis, 2019, 69(9): 1509-1516.
with RTS, S/AS01 E vaccine with or without seasonal malaria [23] Iyamu U, Vinals DF, Tornyigah B, et al. A conserved epitope in
chemoprevention in children up to the age of 5 years in Burkina VAR2CSA is targeted by a cross-reactive antibody originating
Faso and Mali: a double-blind, randomised, controlled, phase 3 from Plasmodium vivax Duffy binding protein[J]. Front Cell In-
trial[J]. Lancet Infect Dis, 2024, 24(1): 75-86. fect Microbiol, 2023, 13: 1202276.
[8] Collins KA, Snaith R, Cottingham MG, et al. Enhancing protec- [24] Shukla N, Tang WK, Coelho CH, et al. A human antibody epi-
tive immunity to malaria with a highly immunogenic virus-like tope map of the malaria vaccine antigen Pfs25[J]. NPJ Vac-
particle vaccine[J]. Sci Rep, 2017, 7: 46621. cines, 2023, 8(1): 108.
[9] Datoo MS, Dicko A, Tinto H, et al. Safety and efficacy of [25] Singh K, Burkhardt M, Nakuchima S, et al. Structure and func-
malaria vaccine candidate R21/Matrix-M in African children: a tion of a malaria transmission blocking vaccine targeting Pfs230
multicentre, double-blind, randomised, phase 3 trial[J]. Lancet, and Pfs230-Pfs48/45 proteins[J]. Commun Biol, 2020, 3(1):
2024, 403(10426): 533-544. 395.
[10] Hanboonkunupakarn B, Mukaka M, Jittamala P, et al. A ran- [26] Sagara I, Healy SA, Assadou MH, et al. Safety and immuno-
domised trial of malaria vaccine R21/Matrix-M™ with and genicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking
without antimalarial drugs in Thai adults[J]. NPJ Vaccines, vaccine against Plasmodium falciparum: a randomised, double-
2024, 9(1): 124. blind, comparator-controlled, dose-escalation study in healthy
[11] Duffy PE. Current approaches to malaria vaccines[J]. Curr Opin Malian adults[J]. Lancet Infect Dis, 2018, 18(9): 969-982.
Microbiol, 2022, 70: 102227. [27] MacDonald NJ, Singh K, Reiter K, et al. Structural and im-
[12] Duffy PE, Gorres JP. Malaria vaccines since 2000: progress, munological differences in Plasmodium falciparum sexual stage
priorities, products[J]. NPJ Vaccines, 2020, 5(1): 48. transmission-blocking vaccines comprised of Pfs25-EPA
[13] Mwakingwe-Omari A, Healy SA, Lane J, et al. Two chemoat- nanoparticles[J]. NPJ Vaccines, 2023, 8(1): 56.
tenuated PfSPZ malaria vaccines induce sterile hepatic immuni- [28] Healy SA, Anderson C, Swihart BJ, et al. Pfs230 yields higher
ty[J]. Nature, 2021, 595(7866): 289-294. malaria transmission-blocking vaccine activity than Pfs25 in hu-
[14] Walker IS, Rogerson SJ. Pathogenicity and virulence of malar- mans but not mice[J]. J Clin Invest, 2021, 131(7): e146221.
ia: sticky problems and tricky solutions[J]. Virulence, 2023, [29] Sagara I, Healy SA, Assadou MH, et al. Malaria transmission-
14(1): 2150456. blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydro-
[15] Blank A, Fürle K, Jäschke A, et al. Immunization with full- gel in healthy Malian adults; a phase 1, randomised, controlled